Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India

BMC Infectious Diseases

Volumn 6, Issue , 2006, Pages

  Tiwari, Hare Krishna ^a   Sen, Malay Ranjan ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BACTERIAL PROTEIN; CHLORAMPHENICOL; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; NETILMICIN; NITROFURANTOIN; NORFLOXACIN; OXACILLIN; PENICILLIN BINDING PROTEIN 2A; PENICILLIN G; SULPERAZON; TEICOPLANIN; TETRACYCLINE; TOBRAMYCIN; VANCOMYCIN;

ADULT; AGAR GEL DIFFUSION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; GENE IDENTIFICATION; HUMAN; INDIA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE; TERTIARY HEALTH CARE;

ANTI-BACTERIAL AGENTS; COMMUNICABLE DISEASES, EMERGING; CROSS INFECTION; HOSPITALS; HUMANS; INDIA; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 33750900242     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-6-156     Document Type: Article

References (33)

1. Lowy FD: Staphylococcus aureus infections. New Engl J Med 1998, 339:520-532.
2. Chambers HF: Methicillin resistance in Staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev 1997, 10:781-791.
3. Brumfil W, Hamilton-Miller J: Methicillin resistant Staphylococcus aureus. N Engl J Med 1989, 320:1188-1196.
4. Ena J, Dick RW, Jones RN, Wenzel RP: The epidemiology of intravenous vacomycin usage in a university hospital: a 10 year study. JAMA 1993, 269:598-602.
5. Cunha BA: Vancomycin. Med Clin North Am 1995, 79:817-831.
6. Tenover FC, Biddle JW, Lancaster MV: Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Inf Dis 2001, 7:327-332.
7. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC: Methicillin resistant Staphylococcus aureus clinicalstrain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997, 40:135-136.
8. Centers for Disease Control and Prevention: Staphylococcus aureus with reduced susceptibility to vancomycin United States, 1997. Morb Mortal Wkly Rep MMWR 1997, 46:765-766.
9. Centers for Disease Control and Prevention: Staphylococcus aureus resistant to vancomycin - United States, 2002. Morb Mortal Wkly Rep MMWR 2002, 51:565-567.
10. Palazzo ICV, Araujo MLC, Darini ALC: First Report of Vancomycin-Resistant Staphylococci Isolated from Healthy Carriers in Brazil. J Clin Microbiol 2005, 43:179-185.
11. Bataineh AB: Resistance of Staphylococcus aureus to Vancomycin in Zarqa, Jordan. Pak J Med Sci 2006, 22:144-148.
12. Smith TL, Pearson LM, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR: Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999, 340:493-501.
13. Rotun SS, McMath V, Schoonmaker DJ, Maupin PS, Tenover FC, Hill BC, Ackman DM: Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999, 5:147-149.
14. Centers for Disease Control and Prevention: Staphylococcus aureus with reduced susceptibility to vancomycin-Illinois, 1999. Morb Mortal Wkly Rep MMWR 2000, 48:1165-1167.
15. Ploy MC, Grelaud C, Martin C, de Lumley L, Denis F: Firstclinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 1998, 351:1212.
16. Howe PA, Bowker KE, Walsh TR,, Feast TG, MacGowan AP: Vancomycin-resistant Staphylococcus aureus. Lancet 1998, 351:602.
17. Bierbaum G, Fuchs K, Lenz W, Szekat C, Sahl HG: Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. Eur J Clin Microbiol Infect Dis 1999, 18:691-696.
18. Assadullah S, Kakru DK, Thoker MA, Bhat FA, Hussain N, Shah A: Emergence of low level vancomycin resistance in MRSA. Indian J Med Microbiol 2003, 21:196-198.
19. Baird D: Staphylococcus: cluster forming gram positive cocci. In Mackie and McCartney Practical Medical Microbiology 14th edition. Edited by: Collee JG, Fraser AG, Marmion BP, Simmons A. New York: Churchill Livingstone; 1996:245-261.
20. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A5. In NCCLS 5th edition. Wayne, PA, USA, 2000.
21. Maniatis T, Fritsch EF, Sambrook J: Molecular Cloning: a Laboratory Manual Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1982.
22. Geha DJ, Uhl JR, Gustaferro CA, Persing DH: Multiplex PCR for identification of methicillin-resistant staphylococci in the clinical laboratory. J Clin Microbiol 1994, 32:1768-1772.
23. Clark NC, Cooksey RC, Hill BC, Swenson JM, Tenover FC: Characterization of glycopeptide-resistant enterococci from U. S. hospitals. Antimicob Agents Chemother 1993, 37:2311-2317.
24. Song JH, Hiramatsu K, Suh JY, Ko KS, Ito T, Kapi M, Kiem S, Kim YS, Oh WS, Peck KR, Lee NY, Asian Network for Surveillance of Resistant Pathogens Study Group: Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2004, 48:4926-4928.
25. Holloway K: Antimicrobial resistance: the facts. Essential Drug Monitor WHO 2000, 28&29:7-8.
26. Noble WC, Virani Z, Cree RC: Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992, 72:195-198.
27. Showsh SA, De Boever RH, Clewell DB: Vancomycin resistance plasmid in Enterococcus faecolis that encodes sensitivity to a sex pheromone also produced by Staphylococcus aureus. Antimicrob Agents Chemother 2001, 45:2177-2178.
28. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, H Labischinski H, Hiramatsu K: Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother 1998, 42:199-209.
29. Hanaki H, Labischinski H, Inaba Y, Kondo N, Murakami H, Hiramatsu K: Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. J Antimicrob Chemother 1998, 42:315-320.
30. Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K: Contribution of a thickened cell wall and its gultamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. J Antimicrob Chemother 2000, 44:2276-2285.
31. Marchese A, Balistreri G, Tonoli E, Debbia EA, Schito GC: Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital. J Clin Microbiol 2000, 38:866-869.
32. Rotun SS, McMath V, Schoonmaker DJ, Maupin PS, Tenover FC, Hill BC, Ackman DM: Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999, 5:147-149.
33. Hiramatsu K: Vancomycin resistance in staphylococci. Drug Resistance Updates 1998, 1:135-150.